title: Empirical first-line treatment with tigecycline for febrile episodes following abdominal surgery in cancer patients.
abstract: Cancer patients with complicated infections following abdominal surgery represent one of the worst clinical scenarios that is useful for testing the efficacy of empirical antimicrobial therapy. No study so far has evaluated the performance of tigecycline (TIG) when administered as empirical first-line treatment in a homogeneous population of surgical cancer patients with a febrile episode. An observational review of the data records of 24 sequential patients receiving TIG for a febrile episode following a major abdominal procedure in a single cancer institute was performed. Large bowel surgery represented 68% of all procedures, followed by gastric surgery (16%) and urinary-gynaecologic-biliary surgery (16%). Complications following surgery were observed in 68% of febrile episodes, with peritonitis and sepsis accounting for 59% and 24% of complications, respectively. Eight patients needed repeat surgery for source control. The mean duration of TIG treatment was 8 days. Causative pathogens were detected in 16 episodes (64%), and a total of 44 microorganisms were recovered (29% Escherichia coli, 9% Enterococcus faecalis and 9% coagulase-negative staphylococci). TIG was effective in 12 episodes (48%). The success rate was 67% when infectious episodes sustained by intrinsically resistant bacteria and fungi were excluded. Treatment failure was associated with the presence of complications and with microbiologically documented infection. TIG may be useful as a first-line treatment option in cancer patients requiring antibiotic treatment following surgery when complications are not present or suspected on clinical grounds and when local microbial epidemiology shows a low incidence of primary resistant bacteria.
authors.affiliation: SS Infettivologia, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Secondo
authors.forename: Francesca
authors.initials: F
authors.lastname: Vassallo
authors.forename: Nicola
authors.initials: N
authors.lastname: Solari
authors.forename: Luciano
authors.initials: L
authors.lastname: Moresco
authors.forename: Pierluigi
authors.initials: P
authors.lastname: Percivale
authors.forename: Lucia
authors.initials: L
authors.lastname: Zappi
authors.forename: Ferdinando
authors.initials: F
authors.lastname: Cafiero
authors.forename: Andrea
authors.initials: A
authors.lastname: De Maria
mesh_terms: D000008:Abdominal Neoplasms / Q000150:complications* / Q000601:surgery*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D013293:Enterococcus faecalis / Q000302:isolation & purification; D004926:Escherichia coli / Q000302:isolation & purification; D005260:Female; D005335:Fever of Unknown Origin / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008911:Minocycline / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009369:Neoplasms / Q000150:complications* / Q000601:surgery*; D010538:Peritonitis / Q000188:drug therapy; D018805:Sepsis / Q000188:drug therapy; D013210:Staphylococcus / Q000302:isolation & purification; D013530:Surgical Wound Infection / Q000188:drug therapy; D000078304:Tigecycline; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D008911:Minocycline